Welcome to our dedicated page for Danaher Corporation news (Ticker: DHR), a resource for investors and traders seeking the latest updates and insights on Danaher Corporation stock.
Danaher Corporation (NYSE: DHR) is a global life sciences and diagnostics innovator whose news flow is closely followed by investors, healthcare professionals and industry observers. The company regularly issues press releases on its financial performance, capital allocation decisions and participation in major healthcare conferences, providing insight into how its life sciences and diagnostics businesses are performing and evolving.
On this page, readers can find news about Danaher’s quarterly and annual results, including updates on revenue trends, non‑GAAP core revenue growth and adjusted earnings, as described in its earnings releases and related Form 8‑K filings. The company frequently hosts earnings conference calls and webcasts, and it posts accompanying slide presentations, non‑GAAP reconciliations and notes on historical and anticipated financial performance in its investors materials.
Danaher also announces regular quarterly cash dividends on its common stock and discloses share repurchase authorizations, giving shareholders visibility into its capital allocation approach. In addition, news items cover leadership and governance developments, such as planned transitions in senior executive roles and changes in board composition, as documented in the company’s communications and SEC reports.
Beyond financial and corporate updates, Danaher’s news includes product and research announcements from its operating companies. For example, Beckman Coulter Diagnostics, a Danaher company, has reported the launch of a fully automated Brain‑derived Tau research use only immunoassay test and the development of an Aβ‑42 research use only immunoassay test to support neurodegenerative disease research. These stories illustrate how Danaher’s diagnostics businesses contribute to advanced clinical and research capabilities.
By reviewing the DHR news feed, users can monitor earnings announcements, dividend declarations, conference presentations, governance updates and scientific developments across Danaher’s life sciences and diagnostics platform. This page can be a useful resource for tracking how the company communicates its strategy, performance and innovation activities over time.
Danaher Corporation (NYSE: DHR) announced that CEO Rainer M. Blair will present at the Bank of America Securities Health Care Conference in Las Vegas, Nevada, on May 11, 2022, at 10:00 a.m. PT. The event will be webcast live on Danaher’s official website. Danaher is a global innovator in science and technology, focusing on solving complex challenges in health care, environmental, and applied markets. With approximately 80,000 associates, Danaher operates through over 20 companies united by its business system and shared purpose of 'Helping Realize Life's Potential.'
Danaher Corporation (NYSE: DHR) announced its Q1 2022 results, reporting net earnings of $1.7 billion ($2.31 per diluted share), marking a 1.0% year-over-year increase. Non-GAAP adjusted diluted net earnings rose 9.5% to $2.76 per share. Revenues hit $7.7 billion, reflecting a 12.0% increase, with 12.0% non-GAAP core revenue growth. Operating cash flow stood at $2.0 billion. For Q2 2022, non-GAAP base business core revenue growth is projected in the mid-single digits, impacted by COVID-19 shutdowns in China. The full year 2022 growth is expected in the high-single digits.
Danaher Corporation (NYSE: DHR) announced that its 4.75% Series A Mandatory Convertible Preferred Stock will convert into common stock on April 15, 2022. Each share of Preferred Stock will convert at a rate of 6.6632 shares of Common Stock. Holders of record as of March 31, 2022, will also receive a final quarterly cash dividend of $11.875 per share on the Preferred Stock. This move reflects Danaher's commitment to enhancing shareholder value and streamlining capital structure.
Integrated DNA Technologies (IDT) has partnered with Catalytic Data Science as part of its Align Program to enhance next-generation sequencing (NGS) solutions. Catalytic Data Science will promote IDT's rhAmpSeq CRISPR Analysis System, which integrates advanced data analysis technology with IDT's CRISPR genome editing reagents. This collaboration aims to improve the efficiency of genomic research and was highlighted by a 2021 award for innovation. IDT, known for its nucleic acid products, supports over 130,000 life science researchers globally.
Danaher Corporation (NYSE: DHR) will host a quarterly earnings conference call for Q1 2022 on April 21, 2022, at 8:00 a.m. ET. The call can be accessed via webcast on Danaher's website in the Investors section, alongside a presentation. A replay will be available after the call until May 5, 2022, and can be accessed via phone or the website. Danaher, a leader in healthcare and technology, aims to aid customers in overcoming challenges globally, boasting a team of approximately 80,000 associates.
Integrated DNA Technologies (IDT) has announced that the Munich Leukemia Laboratory (MLL) has joined its Align Program, following the launch of IDT's xGen™ NGS portfolio in December. This partnership aims to promote genomics research by leveraging MLL's expertise in sequencing exomes, genomes, and transcriptomes, along with IDT's advanced NGS solutions. MLLSEQ, MLL's sequencing label, will now be available to researchers beyond healthcare. The Align Program enhances access to innovative NGS tools, contributing to advancements in cancer research and diagnostics.
Danaher Corporation (NYSE: DHR) announced that its CEO, Rainer M. Blair, will present at the Cowen Healthcare Conference on March 8, 2022, at 9:10 a.m. ET. The presentation will be available via a live webcast on www.danaher.com. Danaher is a global leader in science and technology, focused on improving quality of life and solving complex challenges across health care, environmental, and applied markets. With over 80,000 associates, Danaher upholds a strong operational culture through its Danaher Business System.
Danaher Corporation (NYSE: DHR) has declared a quarterly cash dividend of $0.25 per share for common stock, payable on April 29, 2022, to shareholders on record by March 25, 2022. Additionally, dividends for preferred stocks include $11.875 for its 4.75% Series A and $12.50 for its 5.00% Series B, both payable on April 15, 2022, to shareholders on record by March 31, 2022. This indicates continued shareholder returns and reflects the company’s confidence in its financial health.
Danaher Corporation (NYSE: DHR) announced strong financial results for Q4 and full year 2021. Q4 net earnings reached $1.8 billion, or $2.39 per share, a 44% increase year-over-year, with revenues of $8.1 billion, up 20.5%. Full year net earnings were $6.3 billion ($8.50 per share), a 74% rise, while revenues increased 32% to $29.5 billion. Operating cash flow rose 34.5% to $8.4 billion. CEO Rainer M. Blair highlighted a transformative year with strategic acquisitions totaling $11 billion and a strong foundation for future growth. The company projects high-single digit core revenue growth for 2022.
Pall Corporation, a subsidiary of Danaher, unveiled the Supralon hydraulic and lube oil filter element range on January 11, 2022. This product upgrade enhances existing filter lines, employing stress-resistant technology for better equipment protection. It promises reduced energy costs and lower maintenance expenses, thereby decreasing total filtration costs. Supralon filters match the form and function of previous models and can retrofit into existing systems to improve fluid cleanliness. The older filter models will be phased out in the coming months.